1-17 of 17
Srikanth R. Ambati
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Evaluate Dynamics of IL-6 Release during Step-up Dosing of Subcutaneous Administration of Odronextamab Via a Quantitative Systems Pharmacology Modeling Approach

Masood Khaksar Toroghi, Min Zhu, Srikanth R. Ambati, Hesham Mohamed, Aafia Chaudhry, Hong Yan, John D. Davis, A. Thomas DiCioccio
Journal: Blood
Blood (2022) 140 (Supplement 1): 11912–11913.
https://doi.org/10.1182/blood-2022-158413
Published: 2022
Journal Articles

Modeling and Simulation in Support of Odronextamab Subcutaneous Dose Selection for Adult Patients with Indolent or Aggressive Non-Hodgkin Lymphoma

Min Zhu, Srikanth R. Ambati, Hesham Mohamed, Masood Khaksar Toroghi, Hong Yan, Aafia Chaudhry, John D. Davis
Journal: Blood
Blood (2022) 140 (Supplement 1): 11579–11580.
https://doi.org/10.1182/blood-2022-158409
Published: 2022
Journal Articles

Selection of Odronextamab Pediatric Dosing Regimens for Aggressive Non-Hodgkin Lymphoma Via a Modeling and Simulation Approach

Min Zhu, Michael Dodds, Srikanth R. Ambati, Hesham Mohamed, Jason Chittenden, Hong Yan, Aafia Chaudhry, John D. Davis
Journal: Blood
Blood (2022) 140 (Supplement 1): 8855–8856.
https://doi.org/10.1182/blood-2022-158416
Published: 2022
Journal Articles

Optimization of Intravenous Odronextamab Step-up Regimen for Reducing the Risk of High-Grade Cytokine Release Syndrome

Min Zhu, Jurriaan Brouwer-Visser, Srikanth R. Ambati, Hesham Mohamed, Vladimir Jankovic, Fang Wang, Hong Yan, Jingxian Cai, Carolina Leite De Oliveira, Melanie Ufkin, John D. Davis, Aafia Chaudhry, Masood Khaksar Toroghi
Journal: Blood
Blood (2022) 140 (Supplement 1): 11560–11561.
https://doi.org/10.1182/blood-2022-158415
Published: 2022
Journal Articles

Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2

Won-Seog Kim, Tae Min Kim, Seok-Goo Cho, Isidro Jarque, Elżbieta Iskierka-Jażdżewska, Michelle Limei Poon, H. Miles Prince, Sung Yong Oh, Francesca Lim, Cecilia Carpio, Tran-Der Tan, Sabarish Ayyappan, Antonio Gutierrez, Jingjin Li, Melanie Ufkin, Min Zhu, Aafia Chaudhry, Hesham Mohamed, Srikanth R. Ambati, Jan Walewski
Journal: Blood
Blood (2022) 140 (Supplement 1): 1070–1071.
https://doi.org/10.1182/blood-2022-158406
Published: 2022
Journal Articles

A Quantitative Systems Pharmacology Modeling Framework for Evaluation of Cytokine Release Mediated By Intravenous Odronextamab Monotherapy in Patients with B-Cell Non-Hodgkin Lymphoma

Masood Khaksar Toroghi, Min Zhu, Jurriaan Brouwer-Visser, Srikanth R. Ambati, Hesham Mohamed, Aafia Chaudhry, John D. Davis, A. Thomas DiCioccio
Journal: Blood
Blood (2022) 140 (Supplement 1): 11930–11931.
https://doi.org/10.1182/blood-2022-158412
Published: 2022
Journal Articles

Odronextamab in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Grade 1-3a: Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2

Tae Min Kim, Michal Taszner, Seok-Goo Cho, Silvana Novelli, Steven Le Gouill, Michelle Limei Poon, Jose C. Villasboas, Rebecca Champion, Emmanuel Bachy, Stéphanie Guidez, Aránzazu Alonso Alonso, Deepa Jagadeesh, Michele Merli, David Tucker, Jingxian Cai, Carolina Leite De Oliveira, Min Zhu, Aafia Chaudhry, Hesham Mohamed, Srikanth R. Ambati, Stefano Luminari
Journal: Blood
Blood (2022) 140 (Supplement 1): 2280–2282.
https://doi.org/10.1182/blood-2022-158404
Published: 2022
Journal Articles

Trial in Progress: Follicular Lymphoma Outcomes in Relapsed/Refractory Patients Treated with Systemic Therapy in a Real-World Assessment (FLORA)

Emmanuel Bachy, Gandhi Laurent Damaj, Qiufei Ma, Christian Hampp, James Harnett, Rachel E. Sobel, Jessica J. Jalbert, Ruben G.W. Quek, Wenhui Wei, Ning Wu, Vera Mastey, Joy Wang, Anit Bajwa, Benedikt Maissenhaelter, Chantal van Gils, Shivani Aggarwal, Aafia Chaudhry, Hesham Mohamed, Srikanth R. Ambati, Catherine Thieblemont
Journal: Blood
Blood (2022) 140 (Supplement 1): 5198–5200.
https://doi.org/10.1182/blood-2022-158419
Published: 2022
Journal Articles

Trial in Progress: Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Systemic Therapy from Real-World Experience (ORCHID)

Catherine Thieblemont, Qiufei Ma, Christian Hampp, James Harnett, Rachel E. Sobel, Jessica J. Jalbert, Ruben G.W. Quek, Wenhui Wei, Ning Wu, Vera Mastey, Joy Wang, Anit Bajwa, Benedikt Maissenhaelter, Chantal van Gils, Shivani Aggarwal, Aafia Chaudhry, Hesham Mohamed, Srikanth R. Ambati, Emmanuel Bachy, Gandhi Laurent Damaj
Journal: Blood
Blood (2022) 140 (Supplement 1): 8065–8067.
https://doi.org/10.1182/blood-2022-158418
Published: 2022
Journal Articles

Baseline Biomarkers of T-Cell Function Correlate with Clinical Responses to Odronextamab (REGN1979), and Loss of CD20 Target Antigen Expression Identified As a Mechanism of Treatment Resistance

Jurriaan Brouwer-Visser, PhD, Nathalie Fiaschi, PhD, Raquel P. Deering, PhD, Ankur Dhanik, PhD, Kamil J. Cygan, PhD, Wen Zhang, PhD, Se Jeong, MPH, Stephane Pourpe, MS, Lauren Boucher, Sara Hamon, PhD, Max S. Topp, MD, Rajat Bannerji, MDPhD, Johannes Duell, MD, Ranjana Advani, MD, Dina M. Flink, PhD, Aafia Chaudhry, MD MBA, MS, Andres Sirulnik, MD PhD, Andrew J. Murphy, PhD, David M. Weinreich, MD, George D. Yancopoulos, MD PhD, Gavin Thurston, PhD, Srikanth R. Ambati, MBBS, MD, Vladimir Jankovic, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 10–11.
https://doi.org/10.1182/blood-2020-137499
Published: 2020
Journal Articles

A Phase 2 Study of Odronextamab (REGN1979), a CD20 x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Tae Min Kim, MD PhD, Arancha Alonso, MD, Miles Prince, MD, Michal Taszner, MD, Seok-Goo Cho, MD, PhD, Don A. Stevens, MD, Michelle Poon, MD, Francesca Lim, MBBS, BSc, MRCP (UK), Steven Le Gouill, MD PhD, Cecilia Carpio, MD, Mary-Margaret Keating, MD FRCPC, Lieve Adriaens, PharmD, Melanie Ufkin, PhD, Ayesha Sabir, BSc, Jingjin Li, PhD, Vladimir Jankovic, MD, Min Zhu, PhD, Jurriaan Brouwer-Visser, PhD, Siyang Leng, MD MS, L. Andres Sirulnik, MD PhD, Aafia Chaudhry, MD MBA, MS, Srikanth R. Ambati, MBBS, MD, Kim Won Seog, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 28–29.
https://doi.org/10.1182/blood-2020-136344
Published: 2020
Journal Articles

Odronextamab (REGN1979), a Human CD20 x CD3 Bispecific Antibody, Induces Durable, Complete Responses in Patients with Highly Refractory B-Cell Non-Hodgkin Lymphoma, Including Patients Refractory to CAR T Therapy

Rajat Bannerji, MDPhD, John N. Allan, MD, Jon E. Arnason, MD, Jennifer R. Brown, MD PhD, Ranjana Advani, MD, Stephen M. Ansell, MD PhD, Susan M. O'Brien, MD, Johannes Duell, MD, Peter Martin, FRCPC, MD MS, Robin M. Joyce, MD, Jingjin Li, PhD, Dina M. Flink, PhD, Min Zhu, PhD, David M. Weinreich, MD, George D. Yancopoulos, MD PhD, Andres Sirulnik, MD PhD, Aafia Chaudhry, MD MBA, MS, Srikanth R. Ambati, MBBS, MD, Max S. Topp, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 42–43.
https://doi.org/10.1182/blood-2020-136659
Published: 2020
Journal Articles

Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)

Rajat Bannerji, MD PhD, John N. Allan, MD, Jon E. Arnason, MD, Jennifer R. Brown, MD PhD, Ranjana H Advani, MD, Jeffrey A. Barnes, MD PhD, Stephen M Ansell, MD PhD, Susan M. O'Brien, MD, Julio Chavez, Johannes Duell, MD, Kevin A. David, MD, Peter Martin, FRCPC, MD MS, Robin M. Joyce, MD, Robert Charnas, PhD, Srikanth R. Ambati, MBBS, MD, Lieve Adriaens, PharmD, Melanie Ufkin, PhD, Min Zhu, PhD, Jingjin Li, PhD, Peter Gasparini, MS, Anfal Ibrahim, BS, Vladimir Jankovic, MD, Nathalie Fiaschi, PhD, Olulanu Aina, PhD, Wen Zhang, PhD, Raquel P. Deering, PhD, Sara Hamon, PhD, Gavin Thurston, PhD, Andrew J. Murphy, PhD, David M. Weinreich, MD, George D. Yancopoulos, MD PhD, Israel Lowy, MD PhD, David Sternberg, MD PhD, Max S. Topp, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 762.
https://doi.org/10.1182/blood-2019-122451
Published: 2019
Journal Articles

A Phase 2 Study of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody (Ab), in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)

Max S. Topp, MD, Johannes Duell, MD, Jingjin Li, PhD, Vladimir Jankovic, MD, Israel Lowy, MD PhD, David Sternberg, MD PhD, Lieve Adriaens, PharmD, Mary Peterman, PharmD, Srikanth R. Ambati, MBBS, MD, Rajat Bannerji, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4007.
https://doi.org/10.1182/blood-2019-126670
Published: 2019
Journal Articles

Pre-Clinical Evaluation of a Novel DNA Crosslinking Agent, Bo-1055 in B-Cell Lymphoma

Eloisi Caldas Lopes, Fabian Correa, Elizabeth Peguero, Srikanth R. Ambati, MBBS, MD, Jae Hung Shieh, Tsann Long SU, Malcolm A.S. Moore
Journal: Blood
Blood (2014) 124 (21): 5483.
https://doi.org/10.1182/blood.V124.21.5483.5483
Published: 2014
Journal Articles

Monitoring Cardiac Siderosis in Patients with Beta-Thalassemia Major on Various Chelation Regimens,

Srikanth R. Ambati, MBBS, MD, Rachel Randolph, B.S., Kevin Mennitt, MD, Dorothy A Kleinert, NP, MPH, Patricia Giardina, MD
Journal: Blood
Blood (2011) 118 (21): 3177.
https://doi.org/10.1182/blood.V118.21.3177.3177
Published: 2011
Journal Articles

Serial Measurements of Cardiac and Hepatic Iron with MRI T2* In Transfusion Dependent Patients with Beta-Thalassemia Major Receiving Deferasirox

Srikanth R. Ambati, MBBS, MD, Dorothy A. Kleinert, NP, MPH, Patricia J. Giardina, MD
Journal: Blood
Blood (2010) 116 (21): 2051.
https://doi.org/10.1182/blood.V116.21.2051.2051
Published: 2010